Dynamic Technology Lab Private Ltd purchased a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) during the 1st quarter, Holdings Channel reports. The institutional investor purchased 9,479 shares of the company’s stock, valued at approximately $339,000.
Several other large investors have also recently made changes to their positions in CRSP. ARK Investment Management LLC boosted its stake in shares of Crispr Therapeutics by 52.7% during the 1st quarter. ARK Investment Management LLC now owns 2,023,017 shares of the company’s stock worth $72,262,000 after acquiring an additional 697,907 shares in the last quarter. Versant Venture Management LLC raised its position in shares of Crispr Therapeutics by 17.7% during the 1st quarter. Versant Venture Management LLC now owns 4,248,888 shares of the company’s stock worth $151,770,000 after purchasing an additional 640,014 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new position in shares of Crispr Therapeutics during the 4th quarter worth approximately $16,598,000. Nikko Asset Management Americas Inc. raised its position in shares of Crispr Therapeutics by 47,632.0% during the 1st quarter. Nikko Asset Management Americas Inc. now owns 441,044 shares of the company’s stock worth $15,754,000 after purchasing an additional 440,120 shares during the last quarter. Finally, Two Sigma Investments LP raised its position in shares of Crispr Therapeutics by 25.2% during the 4th quarter. Two Sigma Investments LP now owns 509,572 shares of the company’s stock worth $14,558,000 after purchasing an additional 102,478 shares during the last quarter. 48.96% of the stock is currently owned by institutional investors and hedge funds.
Shares of CRSP opened at $43.27 on Friday. The company has a current ratio of 15.84, a quick ratio of 15.84 and a debt-to-equity ratio of 0.08. Crispr Therapeutics AG has a fifty-two week low of $22.22 and a fifty-two week high of $66.72.
Crispr Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Monday, April 29th. The company reported ($0.93) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.03). The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $1.50 million. Crispr Therapeutics had a negative net margin of 8,839.02% and a negative return on equity of 50.90%. The company’s revenue was down 78.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.62) earnings per share. Analysts predict that Crispr Therapeutics AG will post -3.82 EPS for the current year.
Several brokerages recently issued reports on CRSP. Zacks Investment Research upgraded Crispr Therapeutics from a “hold” rating to a “buy” rating and set a $40.00 price objective for the company in a research report on Friday, March 1st. Chardan Capital set a $73.00 price objective on Crispr Therapeutics and gave the stock a “buy” rating in a research report on Friday, June 7th. Roth Capital began coverage on Crispr Therapeutics in a research report on Monday, June 10th. They set a “buy” rating and a $50.00 price objective for the company. Evercore ISI began coverage on Crispr Therapeutics in a research report on Thursday, April 11th. They set an “outperform” rating for the company. Finally, BidaskClub upgraded Crispr Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. Three research analysts have rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $48.00.
In other Crispr Therapeutics news, CEO Samarth Kulkarni sold 20,000 shares of the business’s stock in a transaction on Monday, April 29th. The stock was sold at an average price of $42.03, for a total value of $840,600.00. Following the completion of the transaction, the chief executive officer now directly owns 186,542 shares in the company, valued at approximately $7,840,360.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, President Rodger Novak sold 50,000 shares of the business’s stock in a transaction on Monday, June 10th. The shares were sold at an average price of $45.00, for a total value of $2,250,000.00. Following the completion of the transaction, the president now owns 898,007 shares of the company’s stock, valued at $40,410,315. The disclosure for this sale can be found here. Insiders own 37.70% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: “Dynamic Technology Lab Private Ltd Purchases Shares of 9,479 Crispr Therapeutics AG (NASDAQ:CRSP)” was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another website, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this story can be viewed at https://www.thestockobserver.com/2019/06/16/dynamic-technology-lab-private-ltd-purchases-shares-of-9479-crispr-therapeutics-ag-nasdaqcrsp.html.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Recommended Story: How are dividend achievers different from dividend aristocrats?
Want to see what other hedge funds are holding CRSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crispr Therapeutics AG (NASDAQ:CRSP).
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.